Publikation
Dynamics of tumor-specific cfDNA in response to therapy in multiple myeloma patients
Wissenschaftlicher Artikel/Review - 25.11.2019
Vrabel David, Sevcikova Sabina, Pour Ludek, Stork Martin, Sandecka Viera, Jelinek Tomas, Plonkova Hana, Jarkovsky Jiri, Brožová Lucie, Kubaczkova Veronika, Almasi Martina, Bezdekova Renata, Rihova Lucie, Besse Lenka, Sedlarikova Lenka, Hájek Roman
Bereiche
PubMed
DOI
Zitation
Art
Zeitschrift
Veröffentlichungsdatum
eISSN (Online)
Kurzbeschreibung/Zielsetzung
OBJECTIVES
Progress in multiple myeloma treatment allows patients to achieve deeper responses, for which the assessment of minimal residual disease (MRD) is critical. Typically, bone marrow samples are used for this purpose; however, this approach is site-limited. Liquid biopsy represents a minimally invasive and more comprehensive technique that is not site-limited, but equally challenging.
METHODS
While majority of current data comes from short-term studies, we present a long-term study on blood-based MRD monitoring using tumor-specific cell-free DNA detection by ASO-qPCR. One hundred and twelve patients were enrolled into the study, but long-term sampling and analysis were feasible only in 45 patients.
RESULTS
We found a significant correlation of quantity of tumor-specific cell-free DNA levels with clinically meaningful events [induction therapy (P = .004); ASCT (P = .012)]. Moreover, length of cfDNA fragments is associated with better treatment response of patients.
CONCLUSIONS
These results support the concept of tumor-specific cell-free DNA as a prognostic marker.